home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Quest Diagnostics (NY:DGX)

190.04 +3.43 (+1.84%)

Streaming Delayed Price Updated: 1:56 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023 ↗

August 02, 2023

Investors looking for bargain stock opportunities in a rapidly-rising market should consider these companies that haven't yet bounced back.

Via InvestorPlace

Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook ↗

July 26, 2023

Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27.

Via Benzinga

Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits ↗

July 25, 2023

At the end of July 25, 2023, Quest Diagnostics (NYSE:DGX) will reward its shareholders with a dividend payout of $0.71 per share, demonstrating an annualized dividend yield of 2.15%. Remember, only...

Via Benzinga

Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades' ↗

July 19, 2023

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Quest Diagnostics Incorporated (NYSE: DGX) here.

Via Benzinga

Quest Diagnostics: Dividend Insights ↗

July 05, 2023

Via Benzinga

Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits ↗

June 30, 2023

The Centers for Medicare and Medicaid Services released revised guidance on using its authority with pharmaceutical manufacturers

Via Benzinga

Analyst Ratings for Quest Diagnostics ↗

June 29, 2023

Via Benzinga

The Latest Analyst Ratings for Quest Diagnostics ↗

May 02, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023 ↗

June 29, 2023

Via Benzinga

FDA Readies Proposal for Increased Oversight on Lab-developed Tests ↗

June 08, 2023

The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify other health issues. The FDA is developing a...

Via Benzinga

Want Growing Passive Income? Consider Buying This Stock ↗

May 24, 2023

This maker of diagnostics tests has delivered 13 years of dividend growth to shareholders.

Via The Motley Fool

Will Chart Analysts Notice Bad Omen on Quest Diagnostics's Chart ↗

May 02, 2023

Via Benzinga

Quest Diagnostics Q1 Earnings Surpass Expectations; COVID-19 Testing Revenues Slump 80% ↗

April 27, 2023

Via Benzinga

Analyst Expectations for Quest Diagnostics's Future ↗

April 03, 2023

Via Benzinga

Analyst Expectations for Quest Diagnostics's Future ↗

March 17, 2023

Via Benzinga

Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds ↗

May 18, 2023

The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis...

Via Benzinga

Exact Sciences Serves Investors Exactly What They Wished For

May 15, 2023

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The

Via MarketBeat

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May ↗

May 11, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023 ↗

May 02, 2023

Via Benzinga

5 Analysts Have This to Say About Quest Diagnostics ↗

January 23, 2023

Via Benzinga

Analyst Ratings for Quest Diagnostics ↗

January 06, 2023

Via Benzinga

UiPath is a Cheaper and More Profitable AI Stock

April 06, 2023

With the mainstream popularity of ChatGPT, artificial intelligence (AI) has been all the rage in 2023. The AI wars between Microsoft Co. (NASDAQ: MSFT) invest

Via MarketBeat

Topics Artificial Intelligence

Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023 ↗

April 03, 2023

Via Benzinga

Where Quest Diagnostics Stands With Analysts ↗

December 14, 2022

Via Benzinga

Quest Diagnostics Inc. (NYSE: DGX) Making Surprising Moves in Friday Session

March 24, 2023

Via Investor Brand Network

Is This Healthcare Stock a Buy for Dividend Growth Investors? ↗

March 07, 2023

This maker of diagnostics tests just announced that it will be sending more cash to its shareholders.

Via The Motley Fool

2 Dividend Stocks That Recently Boosted Their Payouts by More Than 7% ↗

February 15, 2023

These companies may not be finished raising their dividend payments as they both have low payout ratios.

Via The Motley Fool

Down 40% in 2022, Can Exact Sciences Recover in 2023? ↗

January 23, 2023

Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous.

Via The Motley Fool

These 2 Defensive Plays Are Highlights Of CNBC's 'Final Trades' ↗

December 23, 2022

On CNBC’s "Halftime Report: Final Trades," Shannon Saccocia of Boston Private said Quest Diagnostics Inc (NYSE: DGX) is expected to grow 4% to 5%

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023 ↗

January 23, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com